Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.31 Million EUR | 1.17% |
| 2022 | -22.44 Million EUR | -45.11% |
| 2021 | -14.61 Million EUR | -73.21% |
| 2020 | -8.85 Million EUR | 16.44% |
| 2019 | -10.67 Million EUR | -9.16% |
| 2018 | -11.92 Million EUR | -28.34% |
| 2017 | -9.28 Million EUR | -3.46% |
| 2016 | -8.71 Million EUR | -72.86% |
| 2015 | -5.19 Million EUR | -86.04% |
| 2014 | -2.89 Million EUR | -90.74% |
| 2013 | -1.46 Million EUR | -51.84% |
| 2012 | -964.03 Thousand EUR | -50.65% |
| 2011 | -639.91 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -13.57 Million EUR | 0.0% |
| 2023 Q2 | -14.35 Million EUR | 0.0% |
| 2023 Q4 | -10.31 Million EUR | 0.0% |
| 2023 FY | - EUR | 1.17% |
| 2022 Q2 | -13.71 Million EUR | 0.0% |
| 2022 FY | - EUR | -45.11% |
| 2022 Q4 | -13.61 Million EUR | 0.0% |
| 2021 Q2 | -7.58 Million EUR | 0.0% |
| 2021 Q4 | -11.25 Million EUR | 0.0% |
| 2021 FY | - EUR | -73.21% |
| 2020 Q4 | -5.5 Million EUR | 0.0% |
| 2020 Q2 | -5.37 Million EUR | 0.0% |
| 2020 FY | - EUR | 16.44% |
| 2019 Q2 | -6.25 Million EUR | 0.0% |
| 2019 FY | - EUR | -9.16% |
| 2019 Q4 | -6.74 Million EUR | 0.0% |
| 2018 Q2 | -6 Million EUR | 0.0% |
| 2018 Q4 | -5.91 Million EUR | 0.0% |
| 2018 FY | - EUR | -28.34% |
| 2017 FY | - EUR | -3.46% |
| 2017 Q4 | -4.98 Million EUR | 0.0% |
| 2017 Q2 | -4.3 Million EUR | 0.0% |
| 2016 FY | - EUR | -72.86% |
| 2016 Q2 | -4.16 Million EUR | 0.0% |
| 2016 Q4 | -4.81 Million EUR | 0.0% |
| 2015 FY | - EUR | -86.04% |
| 2015 Q4 | -3.72 Million EUR | 0.0% |
| 2015 Q2 | -1.47 Million EUR | 0.0% |
| 2014 FY | - EUR | -90.74% |
| 2014 Q4 | -1.78 Million EUR | -137.33% |
| 2014 Q3 | -752.82 Thousand EUR | 29.34% |
| 2014 Q2 | -1.06 Million EUR | -41.52% |
| 2014 Q1 | -752.82 Thousand EUR | 0.0% |
| 2013 Q3 | -406.29 Thousand EUR | 0.0% |
| 2013 FY | - EUR | -51.84% |
| 2013 Q4 | -752.82 Thousand EUR | -85.29% |
| 2013 Q1 | -406.29 Thousand EUR | 0.0% |
| 2013 Q2 | -406.29 Thousand EUR | 0.0% |
| 2012 Q4 | -406.29 Thousand EUR | -65.5% |
| 2012 FY | - EUR | -50.65% |
| 2012 Q1 | -245.5 Thousand EUR | 0.0% |
| 2012 Q2 | -245.5 Thousand EUR | 0.0% |
| 2012 Q3 | -245.5 Thousand EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q4 | -245.5 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -578.231% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 83.249% |
| Adocia SA | -22.73 Million EUR | 1.84% |
| Aelis Farma SA | -6.34 Million EUR | -251.565% |
| Biophytis S.A. | -13.8 Million EUR | -61.647% |
| Advicenne S.A. | -6.24 Million EUR | -257.364% |
| genOway Société anonyme | 6.35 Million EUR | 451.357% |
| IntegraGen SA | -52.5 Thousand EUR | -42400.061% |
| Medesis Pharma S.A. | -3.84 Million EUR | -480.351% |
| Neovacs S.A. | -8.44 Million EUR | -164.083% |
| NFL Biosciences SA | -4.04 Million EUR | -451.053% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 30864.935% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -676.543% |
| Theranexus Société Anonyme | -7.38 Million EUR | -202.059% |
| TME Pharma N.V. | -5.07 Million EUR | -339.941% |
| Valbiotis SA | -6.95 Million EUR | -220.831% |
| TheraVet SA | -517.33 Thousand EUR | -4213.214% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -17.963% |
| argenx SE | -199.5 Million EUR | 88.815% |
| BioSenic S.A. | -6.79 Million EUR | -228.337% |
| Celyad Oncology SA | -7.76 Million EUR | -187.438% |
| DBV Technologies S.A. | -79.53 Million EUR | 71.943% |
| Galapagos NV | 51.03 Million EUR | 143.721% |
| Genfit S.A. | -28.05 Million EUR | 20.453% |
| GeNeuro SA | -14.31 Million EUR | -55.848% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -48.957% |
| Innate Pharma S.A. | -7.57 Million EUR | -194.455% |
| Inventiva S.A. | -101.84 Million EUR | 78.091% |
| MaaT Pharma SA | -19.74 Million EUR | -13.039% |
| MedinCell S.A. | -20.04 Million EUR | -11.313% |
| Nanobiotix S.A. | -34.01 Million EUR | 34.408% |
| Onward Medical N.V. | -35.23 Million EUR | 36.67% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -403.316% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 4.093% |
| Oxurion NV | -16.72 Million EUR | -33.384% |
| Pharming Group N.V. | 4.98 Million EUR | 547.982% |
| Poxel S.A. | -12.17 Million EUR | -83.215% |
| GenSight Biologics S.A. | -21.73 Million EUR | -2.687% |
| Transgene SA | -27.02 Million EUR | 17.43% |
| Financière de Tubize SA | 184.57 Thousand EUR | 12189.552% |
| UCB SA | 1.26 Billion EUR | 101.758% |
| Valneva SE | -64.51 Million EUR | 65.414% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 21.3% |